NASDAQ:INKT MiNK Therapeutics (INKT) Stock Price, News & Analysis $11.98 -0.22 (-1.76%) As of 01:04 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MiNK Therapeutics Stock (NASDAQ:INKT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MiNK Therapeutics alerts:Sign Up Key Stats Today's Range$11.86▼$12.8050-Day Range$8.56▼$14.2152-Week Range$6.80▼$76.00Volume64,779 shsAverage Volume38,477 shsMarket Capitalization$59.69 millionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingHold Company Overview MiNK Therapeutics, Inc. is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors. MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance. The company has established scalable, GMP‐compatible manufacturing processes to produce engineered exosomes at clinically relevant volumes. Research efforts focus on optimizing biodistribution, payload loading efficiency and safety profiles in animal models, with the goal of advancing IND‐enabling studies for first‐in‐human trials. Headquartered in Cambridge, Massachusetts, MiNK collaborates with academic institutions and contract development organizations across North America and Europe to accelerate its research and development programs. The company’s integrated operations encompass discovery, preclinical testing and process development, supported by a team of experts in exosome biology, translational immunology and biomanufacturing. Through these partnerships and internal capabilities, MiNK aims to bring novel, precision immunotherapies to patients with high‐unmet‐need solid tumors.AI Generated. May Contain Errors. Read More MiNK Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreINKT MarketRank™: MiNK Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 623rd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingMiNK Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside PotentialMiNK Therapeutics has a consensus price target of $35.00, representing about 196.2% upside from its current price of $11.82.Amount of Analyst CoverageMiNK Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about MiNK Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MiNK Therapeutics are expected to decrease in the coming year, from ($2.75) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiNK Therapeutics is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MiNK Therapeutics is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about MiNK Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.18% of the float of MiNK Therapeutics has been sold short.Short Interest Ratio / Days to CoverMiNK Therapeutics has a short interest ratio ("days to cover") of 4.44.Change versus previous monthShort interest in MiNK Therapeutics has recently increased by 26.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMiNK Therapeutics does not currently pay a dividend.Dividend GrowthMiNK Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.62 News SentimentMiNK Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MiNK Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for INKT on MarketBeat in the last 30 days. MarketBeat Follows2 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MiNK Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,137.00 in company stock.Percentage Held by Insiders22.48% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.87% of the stock of MiNK Therapeutics is held by institutions.Read more about MiNK Therapeutics' insider trading history. Receive INKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INKT Stock News HeadlinesMiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical IllnessMay 28, 2026 | globenewswire.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Rating of "Hold" by BrokeragesMay 25, 2026 | americanbankingnews.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.June 2 at 1:00 AM | Porter & Company (Ad)MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology CommunicationsMay 20, 2026 | globenewswire.comWe're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn RateMay 18, 2026 | finance.yahoo.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2026 Earnings Call TranscriptMay 16, 2026 | insidermonkey.comMiNK (INKT) Q4 2025 Earnings Call TranscriptMay 16, 2026 | finance.yahoo.comMiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ...May 16, 2026 | finance.yahoo.comSee More Headlines INKT Stock Analysis - Frequently Asked Questions How have INKT shares performed this year? MiNK Therapeutics' stock was trading at $11.15 at the start of the year. Since then, INKT stock has increased by 6.0% and is now trading at $11.8150. How were MiNK Therapeutics' earnings last quarter? MiNK Therapeutics, Inc. (NASDAQ:INKT) released its quarterly earnings results on Friday, May, 15th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.20. Read the conference call transcript. When did MiNK Therapeutics' stock split? Shares of MiNK Therapeutics reverse split on Tuesday, January 28th 2025.The 1-10 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did MiNK Therapeutics IPO? MiNK Therapeutics (INKT) raised $43 million in an IPO on Thursday, October 14th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share. How do I buy shares of MiNK Therapeutics? Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MiNK Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MiNK Therapeutics investors own include Agenus (AGEN), HubSpot (HUBS), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Bank of America (BAC). Company Calendar Last Earnings5/15/2026Today6/02/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (10m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 INKT's financial health is in the Red zone, according to TradeSmith. INKT has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INKT CIK1840229 Webwww.minktherapeutics.com Phone212-994-8250FaxN/AEmployees30Year Founded2017Price Target and Rating Average Price Target for MiNK Therapeutics$35.00 High Price Target$35.00 Low Price Target$35.00 Potential Upside/Downside+189.8%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.49 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-118.57% Debt Debt-to-Equity RatioN/A Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.03) per share Price / Book-3.99Miscellaneous Outstanding Shares4,980,000Free Float3,862,000Market Cap$60.15 million OptionableNo Data Beta0.47 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:INKT) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our PartnersPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredElon Now Pays 15X More Than Your BankElon Musk's new bank is offering 6% interest per year - that's 15 times the national average of 0.4% that most...InvestorPlace | SponsoredGold hit $4,500 - but these miners haven't caught up yet$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
